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228Background: T-cell receptor (TCR) clonality assessment is a principal diagnostic test in the management
of mycosis fungoides (MF). However, current polymerase chain reactionebased methods may produce
ambiguous results, often because of low abundance of clonal T lymphocytes, resulting in weak clonal
peaks that cannot be size-resolved by contemporary capillary electrophoresis (CE).Objective: We sought to determine if next-generation sequencing (NGS)-based detection has increased
sensitivity for T-cell clonality over CE-based detection in MF.Methods: Clonality was determined by an NGS-based method in which the TCR-g variable region was
polymerase chain reaction amplified and the products sequenced to establish the identity of rearranged
variable and joining regions.Results: Of the 35 MF cases tested, 29 (85%) showed a clonal T-cell rearrangement by NGS, compared with
15 (44%) by standard CE detection. Three patients with MF had follow-up testing that showed identical,
clonal TCR sequences in subsequent skin biopsy specimens.Limitations: Clonal T-cell populations have been described in benign conditions; evidence of clonality
alone, by any method, is not sufficient for diagnosis.Conclusion: TCR clonality assessment by NGS has superior sensitivity compared with CE-based detection.
Further, NGS enables tracking of specific clones across multiple time points for more accurate identification
of recurrent MF. ( J Am Acad Dermatol 2015;73:228-36.)
Key words: cutaneous T-cell lymphoma; molecular diagnostics; mycosis fungoides; next-generation
sequencing; T-cell clonality; T-cell receptor rearrangement.M
ycosis fungoides (MF) is a cutaneous T-cell
lymphoma (CTCL) that accounts for almost
50% of all CTCL, and its incidence in the
United States appears to be increasing.1-3 Classic MF
commonly arises in late adulthood, has a male
predominance, and shows an indolent course,
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Sufficool et al 229of the epidermis often as haloed cells.6 In plaque
stage, this epidermotropism is more pronounced,
and intraepidermal collections of atypical cells
(Pautrier microabscesses) are a characteristic feature,
but are observed in a minority of cases.11 Serial
biopsy specimens are often needed to render a
definitive diagnosis in early patch and plaqueCAPSULE SUMMARY
d Mycosis fungoides often poses a
diagnostic challenge by morphology,
requiring correlation with T-cell clonality
assessment.
d Next-generation sequencing-based
methods for T-cell clonality have superior




methods also allow the tracking of
specific clones when monitoring for
disease recurrence.stages.12,13 In tumor stage,
the infiltrate becomes more
diffuse and tumor cells
increase in both number
and size.5
Immunophenotypically,
the CD31 T lymphocytes
express a T-cell helper
phenotype (CD41) and an
elevated CD4:CD8 ratio is
often seen.14-18 These cells
also express CD45RO.19
There is variable expression
of pan T-cell markers
CD2, CD5, and CD7; loss of
CD2 and CD5 by T cells
can be a helpful finding
in diagnosing CTCL and
supports a diagnosis of
lymphoma.20T-cell receptor (TCR) gene rearrangement
studies can be highly useful in the diagnosis
and monitoring of MF,21 in that the specific
antigen receptor on the cell surface serves as a
marker of neoplastic clonal transformation.22 TCR
molecules are formed as heterodimers composed of
either a and b chains (majority of cases) or g and d
chains. Each of these TCR chains is encoded by
distinct DNA elements known as variable (V),
joining (J), diversity (D), and constant (C)
gene segments. TCR-g gene rearrangement and
expression is thought to occur earliest in
development, followed closely by TCR-d and
TCR-b gene rearrangement.22,23
As most T cells harbor a/b chains, we will focus
on the details of this rearrangement. During
development, the TCR-b chains first undergo a
sequence of ordered recombination events:
Db-to-Jb recombination occurs first, followed by
Vb-to-DbJb rearrangements, and, lastly, all gene
segments between the Vb-Db-Jb gene segments in
the newly formed complex are deleted.23 A primary
transcript is then synthesized that incorporates the C
domain gene (Vb-Db-Jb-Cb). Once a productive b
chain is achieved, the TCR-a gene undergoes rear-
rangement characterized by Va-Ja recombination.
23
Finally, messenger RNA transcription splices out
any intervening sequence and allows translation ofa full-length protein for the a/b TCR chain.23 In the
end, each T cell will have multiple rearranged TCR
loci, not all of which are productive.
TCR sequences are effectively unique to an
individual T lymphocyte because of the immense
diversity created through V(D)J recombination.22,24




diversity. The resulting TCR
gene rearrangement is a
unique ‘‘fingerprint’’ for a
particular T cell.22,24 It bears
mentioning that the evidence
of TCR clonality is not
entirely synonymous for
malignancy and may be
seen in reactive or autoim-
mune conditions.
The most widely used
method for detection of
TCR rearrangements in the
clinical laboratory is poly-
merase chain reaction (PCR)
coupled with capillaryelectrophoresis (CE). Although any TCR chain (a,
b, g, or d) could, in principle, be used for clonality
assessment, the TCR-g locus is preferred over other
loci because it is rearranged early in T-cell
development both in a/b and g/d T cells, can be
PCR amplified using widely available primers
sequences,25,26 and is retained even if the protein is
not expressed on mature T lymphocytes.27 The g
gene structure is also simpler as it has 12 variable
segments; therefore, fewer primer sets are needed to
detect most of the possible gene rearrangements.
Current CE methodology relies on 3 main steps: (1)
extraction of genomic DNA from the skin specimen;
(2) multiplex PCR amplification using standard
primer sets; and (3) detection by electrophoresis to
separate PCR products according to relative
differences in amplicon size.27 Although quantitative
rules are not strictly followed, clonality is generally
defined as the existence of peaks with greater than
2-fold signal intensity above the gaussian
background (Fig 1).28 Although simple in concept,
CE-based detection has several shortcomings. First,
interpretation is subjective, especially in cases where
multiple clonal peaks are present (biclonal or
oligoclonal). Second, because CE only measures
PCR product size as a surrogate for TCR sequence,
it is possible that a monoclonal peak represents a
mixture of different, nonclonal sequences that share
the same size, leading to a false-positive result.29
Fig 1. Capillary electrophoresis (CE) relies on relative
differences in polymerase chain reaction product size. In
CE-based T-cell receptor (TCR) clonality testing the
distribution of amplicon lengths is used to infer clonality.
Normal, polyclonal T cells consist of a mixture of
rearranged TCRs of various sizes that approximate a
gaussian distribution (left). Clonal TCR rearrangements
can be detected when the distribution of TCR amplicons is
restricted, showing only 1 or 2 peaks that are generally
twice the amplitude of the background (right).
Abbreviations used:
CE: capillary electrophoresis
CTCL: cutaneous T-cell lymphoma
MF: mycosis fungoides
NGS: next-generation sequencing
PCR: polymerase chain reaction
TCR: T-cell receptor
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to compare clonal products between primary
diagnostic samples and recurrences because of
technical differences in the assay, including CE
run-to-run variability, especially if testing is
performed in different clinical laboratories.
In contrast, next-generation sequencing (NGS)-
based methods have the advantage of identifying the
exact clonal sequence and its relative abundance in a
given sample (Fig 2). Several studies have shown that
NGS is capable of identifying TCR rearrangement
from formalin-fixed skin tissues.29,30 Further, such
assays can be used to monitor disease recurrence
(Fig 3).31 In the current study, we sought to
determine if NGS-based TCR-clonality detection
methods had increased sensitivity over CE-based
detection in MF.
METHODS
Approval for this study was granted by the
Washington University School of Medicine
Institutional Review Board (October 2011; no.
2011-02311). A 10-year archival review of DNA
samples extracted from formalin-fixed, paraffin-
embedded skin tissue at the Barnes-Jewish Hospital
Molecular Diagnostics Laboratory. Saint Louis, MO,
yielded 34 cases with morphologic features of MF
diagnosed by standard histologic and immunohisto-
chemical assessment (Fig 4). Specifically, these
consecutive skin cases had DNA previously sent to
our clinical molecular laboratory for TCR clonality
assessment and had at least 400 ng remaining for
study; all cases had a morphologically confirmed
diagnoses of MF rendered by subspecialty
board-certified dermatopathologist. Of the 34 cases,
15 were clonal by CE and 19 were polyclonal/
oligoclonal by CE based on clinical TCR clonality
studies reported by a CAP-/CLIA-certified laboratory
using BIOMED-2 TCR-g primers.26 The clinical
characteristics of the 2 cohorts are outlined in Table I.
DNA aliquots from the above 34 cases were
subsequently investigated via NGS-based clonality
assessment. The TCR-g locus was first PCR amplified
using consensus primers that targeted Vg2 to Vg11
and JP1, JP, J1, JP2, and J2 in a single multiplex
reaction.25,30 Each PCR reaction contained 100 ng ofgenomic DNA, 13 HF buffer (New England Biolabs,
Ipswich, MA), 0.2 mmol/L of dNTPs (New England
Biolabs), 0.6 mol/L of each primer (Integrated DNA
Technologies, Coralville, IA) (Supplemental Table I,
available at http://www.jaad.org), and 2 U of
Phusion HS DNA polymerase (New England
Biolabs) in a final volume of 20 L. Specimens
were amplified on an Applied Biosystems (Foster
City, CA) 9700 thermal cycler using the following
cycling conditions: 988C (30 seconds) followed by 30
cycles of 988C (10 seconds), 608C (30 seconds), and
728C (10 seconds plus 1 additional second per cycle).
Quadruplicate PCR reactions were pooled and
column-purified using the MiniElute PCR
purification kit (Qiagen Inc, Valencia, CA), following
the manufacturer’s instructions, with a final elution
volume of 30 L. Concentrations were determined
using a Nanodrop spectrophotometer (Thermo
Scientific).
PCR products were made into sequencing
libraries (Illumina Inc, San Diego, CA) by ligation
of indexed adapters. Purified libraries were mixed in
equimolar ratios and directly sequenced in pools of
10 to 12 cases on MiSeq (Illumina Inc) using 23 150
base pair paired-end reads. To offset possible
redundant sequences occurring early in the read
cycle that may interfere with instrument phasing,
20% (by mass) PhiX DNA was added to the pooled
libraries. Merged contigs (contig, a set of overlapping
DNA sequences) were created based on the
overlapping areas in each pair using the EA utilities
fastq-join function with default parameters.31
Contigs were then counted to determine the most
frequent sequence using the FASTX toolkit collapse
function.32 To account for sequencing and PCR
errors, TCR sequences with fewer than 10 supporting
Fig 2. Next-generation sequencing (NGS)-based T-cell clonality testing. Rather than relying on
the size of T-cell receptor (TCR) region amplicons as a surrogate for TCR sequence, NGS-based
detection methods sequence V and J regions and compare the distribution of unique
sequences. In our analysis method DNA (black) was first amplified using a common set of
publicly available TCR V and J region primers (orange). Amplicons ( gray) were then purified
and made into libraries (Illumina Inc, San Diego, CA) by ligation of sequencer motifs ( pink)
and sample specific indexes ( purple), allowing samples to be pooled and sequenced in
multiplex. Pooled libraries were then sequenced on a MiSeq (Illumina Inc) instrument using 2
3 150 base pair reads. Paired end reads were then collapsed into contigs based on the overlap
between the read pairs (dark gray). Resulting unique sequences were counted to determine the
relative abundance of top-50 most common V region sequences relative to the total number of
sequences. The top-50 sequences were aligned to the IMGT database to determine the identity
of V and J region sequences. Similar to capillary electrophoresisebased methods, if the most
frequent 2 TCR sequences accounted for over 5% of the total reads the case was called ‘‘clonal.’’
PCR, Polymerase chain reaction.
Fig 3. Recurrence detection by next-generation
sequencing (NGS ). A, For cases with multiple biopsy
time points, the identity of the clonal T-cell receptor (TCR)
sequence was first established on the initial biopsy
specimen using the NGS-based method. B, Subsequent
follow-up biopsy specimens were then analyzed to
determine if the same clonal sequence could be identified.
In contrast, standard capillary electrophoresis (CE )-based
methods cannot definitively establish a clonal relationship
between specimens taken at multiple time points as the
assay only measures the size of the amplicon and not the
actual amplicon sequence. HT, Height; sz, size.
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sequences in each case were aligned to the
ImmunoGenetics/IMGT database33 to identify the V
and J regions and assess rearrangement productivity.
Because each T cell will have 2 rearranged TCR-g
loci, of which up to 1 may be productive, the 2 most
common sequences (ie, TCR VJ regions) were
analyzed. Clonal cases were defined as those in
which the 2most common TCRVJ regions accounted
for greater than 5% of total high-quality reads. This
threshold for clonality is comparable with the
traditional 2-fold greater signal in CE-based
methods compared with that identified in nonclonal
dermatoses.25RESULTS
An average of 886,111 paired end reads (range
461 000-4 800 000) were obtained per case, of which
an average of 732,695 were deemed high-quality and
represented an average of 5347 unique TCR
sequences. Depth of coverage was nearly 2 million
reads per case or 500 000 contigs. Of these thousands
of unique sequences, the combination of the 2 most
Fig 4. Mycosis fungoides. A, Representative skin biopsy specimen characterized by a
lymphocytic infiltrate composed of small to medium atypical cerebriform cells demonstrating
epidermotropism. Haloed cells are notable within the epidermis. (Hematoxylin-eosin stain;
original magnification: 320.) B, Lymphocytes were immunoreactive for CD2, CD3, and CD5,
with reduced CD7 positivity. As CD4 also stains Langerhans cells in the epidermis, there are
more CD41 cells than CD31 cells in the epidermis. Because of this, it is important to compare
CD3 and CD8 when examining the epidermal compartment. The CD31CD8 cells likely
correspond to CD41 T cells. CD4 expression was greater than that of CD8. (Immunohisto-
chemistry, original magnification: 320.)









Mean age, y (range) 57.2 (37-76) 57.8 (49-74)
Gender
Male 8/15 (53%) 6/19 (32%)
Female 7/15 (47%) 11/19 (68%)
Race
Caucasian 11/15 (73%) 11/19 (58%)
African American 4/15 (27%) 8/19 (42%)
Location of lesion
Trunk 12 7
Upper extremity 1 6
Lower extremity 1 2
Head and neck 1 4
Histologic stage
Patch 4 (27%) 6 (32%)
Plaque 8 (53%) 8 (42%)
Tumor 3 (20%) 5 (26%)
CE, Capillary electrophoresis; MF, mycosis fungoides; TCR, T-cell
receptor.
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mean of 28% (range 0.8%-80.3%) of all high-quality
reads. TCR-g Vg10 was the most frequently used V
region in 14 of 34 cases (41%) (Supplemental Table
II, available at http://www.jaad.org). With a clonality
cutoff of 5% by NGS (ie, 5% of the total TCR-g reads
coming from the 2 most common sequences), 13 of
15 (86%) CE clonal cases (as determined in a
CAP/CLIA laboratory) were deemed clonal by NGS,
and 16 of 19 (84%) CE polyclonal/oligoclonal cases(as determined in a CAP/CLIA laboratory) were
deemed clonal by NGS. There were 2 cases in which
CEwas positive for TCR rearrangement and NGSwas
negative. In both cases, the most common reads
were 2.5% or 2.4% of total reads, suggesting that a
cutoff lower than 5% may increase sensitivity. Using
histology as a gold standard, the overall sensitivity
was 85% for TCR analysis by NGS (29 of 34 cases,
95% CI 0.70-0.94) and 44% for TCR analysis by
conventional CE (15 of 34 cases, 95% CI 0.29-0.60).
It is unclear what the specificity of this method is as
we did not sequence reactive T-cell conditions. Case
examples are highlighted in Fig 5.
Of positive cases by the NGS method, 3 patients
had subsequent biopsy specimens for comparison,
ranging from 1 to 4 years apart, showing identical
TCR-g sequences by NGS (Fig 6). The first patient
initially presented with an arm lesion harboring a
T-cell receptor gamma, variable region (TRGV)3*01
rearrangement (clonal reads = 9.63%) that was
detectable 1 year later within a new abdominal
lesion (clonal reads = 5.57%). Patient 2 had a
facial lesion with TCR-g variable region 10*01
(V10*01) rearrangement (clonal reads = 74.0%),
which was subsequently identified 2 years later in a
new thigh lesion (clonal reads = 38.7%). Review
of serial biopsy specimens from a third patient,
4 years apart, showed detectable TRGV10*01
rearrangements from 2 separate sites on the upper
extremity (clonal reads = 64.1% and 40.9%,
respectively). For all 3 cases, the percent clonal
reads were higher in initial skin biopsy specimens
than in the follow-up skin samples.
Fig 5. Case examples. Comparison of capillary electrophoresis (CE )- versus next-generation
sequencing (NGS )-based T-cell receptor-g results in a case deemed clonal by both CE and
NGS (A) and a case deemed polyclonal/oligoclonal by CE but clonal by NGS (B). HT, Height;
sz, size; TRGV, T-cell receptor gamma, variable region.
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between clonal V region identity and site or stage
(patch, plaque, or tumor) we performed a Fisher
exact test. There was no apparent correlation
between stage and V region (P = .34) and no
apparent correlation between V region and site.Limitations
The current investigation is a retrospective cohort
study with limited sample size of DNA aliquots from
the molecular laboratory archives. In addition,
there are limitations inherent to T-cell clonality
assessment: (1) tissue sampling is critically important
Fig 6. Next-generation sequencing (NGS)-based T-cell clonality testing is able to detect
identical T-cell receptor (TCR) rearrangements in serial skin biopsy specimens. Of clonal cases,
3 patients (Pt) had follow-up skin sampling, ranging from 1 to 4 years apart, showing identical
TCR clones. The percent clonal reads are noted in parentheses. Detection across multiple time
points highlights a potential role for NGS-based TCR methods in minimal residual disease
testing. TRGV, T-cell receptor gamma, variable region.
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be introduced if the area submitted from the
paraffin-embedded skin is not representative of the
disease process; (2) PCR bias may occur based on the
size and guanine and cytosine content of the TCR-g
sequences in the sample; and (3) CE-based TCR
assays are subject to interpretation because clonality
is based on relative peak size. Although molecular
studies support histologic diagnoses, the astute
dermatologist should bemindful to interpret findings
within the context of available clinical, histologic,
and immunophenotypic data.
DISCUSSION
MF is a diagnostic challenge, with the currently
available CE method for determining TCR clonality
only offering 44% sensitivity in our study, when
compared with the gold standard of histologic
diagnosis. We investigated the use of a NGS-based
detection method in improving the detection of
TCR clonality, and thus of MF. The current
study recognizes that benign/reactive dermatoses
have been shown to harbor a low level of
clonal lymphocytes, and therefore, a conservative
threshold ([5%) for positive clones was established
at twice this baseline (2.5%) to reduce the number of
potential false-positive results.25 An average of 5347
unique TCR sequences were detected in each case;
the 2 most frequent TCR sequences in MF
cases represented a mean of 28% of all reads (range
0.8%-80.3%). Using the proposed cutoff of greaterthan 5% of TCR sequence clonality,25 NGS has a
sensitivity of 88% (95% CI 0.70-0.94) when compared
with the gold standard of histologic diagnosis. We
conclude that NGS-based detection methods for TCR
clonality are a useful adjunct to histologic diagnosis,
and are an improvement over current CE-based
detection methods. NGS not only improves initial
diagnosis of TCR clonality and MF, but may improve
the detection of disease recurrence as well. Once a
specific clonal TCR sequence is identified in the
diagnostic specimen, it may be used as a tumor
marker to track disease progression or monitor for
minimal residual disease.
Our results are comparable with other studies that
have investigated NGS technology in the detection of
andmonitoring for CTCLs. NGS-based methods have
been shown by other investigators to be able to
detect clonal TCR rearrangements in formalin-fixed,
paraffin-embedded biopsy specimens.29 Moreover,
the detection of identical clones from 2 different
body sites has been shown to be quite specific for
MF.35 In hematopoietic malignancies (eg, acute
lymphoblastic leukemia), others have demonstrated
the use of NGS-based assays as highly sensitive
measurements of disease burden.34 Overall, TCR
rearrangement in the assessment of minimal residual
disease piques considerable interest; future studies
are needed to elucidate its clinical use in this setting.
NGS-based methods can be easily incorporated
into the daily practice of the dermatologist/
dermatopathologist as they can be performed on
J AM ACAD DERMATOL
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tissue after routine histologic and immuno-
histochemical examination. NGS technology offers
many exciting clinical applications: (1) as NGS
determines the specific fingerprint of the TCR clone,
it is more sensitive than conventional CE-based
methods and could offer improved MF diagnosis
while patients are in early patch and plaque
stages; (2) once a clone is identified, the
laboratory could query for the specific DNA
sequence in subsequent skin biopsy specimens to
identify low levels of disease that may have been
missed by conventional methods; and (3) although
further studies are needed, NGS may eventually
guide targeted therapies based on detected
molecular signatures.
Conclusion
NGS-based TCR analysis is a clinically relevant
assay that has the potential to expand diagnostic
accuracy, improve monitoring of disease recurrence,
and enhance minimal residual disease testing in MF.
We would like to thank Jessica Hoisington-Lopez from
the Center for Genome Sciences and Systems Biology in St.
Louis, MO for her sequencing expertise.
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Supplemental Table I. Polymerase chain reaction
primers used
JgP1/2: AAG TTA CTA TGA GCY TAG TCC CTT
JgP: AAG CTT TGT TCC GGG ACC AAA TAC
Jg1/2: TAC CTG TGA CAA CAA GTG TTG TTC
Vg11: GGC TCA AGA TTG CTC AGG TGG
Vg10: AAT CCG CAG CTC GAC GCA GCA
Vg9: ACG GCA CTG TCA GAA AGG AAT C
Vg3: CCG CAA GGG ATG TGT TGG AAT CA
Vg2: ACT CCA GGG TTG TGT TGG AAT CA
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Supplemental Table II. T-cell receptor clonality results by capillary electrophoresis compared with next-generation sequencing
Case
Age,




total reads CE result NGS result Clonal 1 ID Clonal 2 ID
1 59 M Caucasian Thigh Patch 38.7% Clonal Clonal TRGV10*01 or TRGV10*02 TRGV9*01
2 61 F Caucasian Flank Plaque 67.5% Clonal Clonal TRGV2*02 TRGV8*01
3* 62 F Caucasian Back Tumor 2.5% Clonal Polyclonal/oligoclonal TRGV2*02 TRGV2*02
4 61 M African American Chest Tumor 33.6% Clonal Clonal TRGV10*01 or TRGV10*02 TRGV9*01
5 37 F African American Back Plaque 11.6% Clonal Clonal TRGV2*02 TRGV2*01
6 37 F African American Back Plaque 11.6% Clonal Clonal TRGV2*02 TRGV2*01
7* 48 M Caucasian Abdomen Patch 2.4% Clonal Polyclonal/oligoclonal TRGV8*01 TRGV4*01
8 62 M Caucasian Chest Plaque 24.0% Clonal Clonal TRGV10*01 or TRGV10*02 TRGV9*01
9 62 M Caucasian Chest Patch 41.8% Clonal Clonal TRGV10*01 or TRGV10*02 TRGV2*01
10 56 F African American Chest Tumor 67.0% Clonal Clonal TRGV9*01 TRGV2*01
11 67 M Caucasian Forearm Plaque 45.0% Clonal Clonal TRGV9*01 TRGV9*01
12 66 F Caucasian Buttock Patch 24.1% Clonal Clonal TRGV8*01 TRGV2*02
13 47 F Caucasian Breast Plaque 43.3% Clonal Clonal TRGV11*01 TRGV9*01
14 76 M Caucasian Back Plaque 38.0% Clonal Clonal TRGV8*01 TRGV3*01
15 57 M Caucasian Face Plaque 74.0% Clonal Clonal TRGV10*01 or TRGV10*02 TRGV9*01
16 55 M African American Back Patch 10.4% Polyclonal/oligoclonal Clonal TRGV10*01 or TRGV10*02 TRGV9*01
17 58 F Caucasian Scalp Patch 8.4% Polyclonal/oligoclonal Clonal TRGV10*01 or TRGV10*02 TRGV10*01 or TRGV10*02
18 49 F Caucasian Abdomen Plaque 15.6% Polyclonal/oligoclonal Clonal TRGV8*01 TRGV3*01
19 57 F African American Arm Tumor 44.3% Polyclonal/oligoclonal Clonal TRGV10*01 or TRGV10*02 TRGV2*02
20 74 F Caucasian Face Tumor 40.9% Polyclonal/oligoclonal Clonal TRGV9*01 TRGV9*01
21* 56 F African American Face Tumor 0.8% Polyclonal/oligoclonal Polyclonal/oligoclonal TRGV10*01 or TRGV10*02 TRGV10*01 or TRGV10*02
22 74 F Caucasian Back Plaque 10.1% Polyclonal/oligoclonal Clonal TRGV4*01 TRGV8*01
23 72 M Caucasian Flank Patch 9.6% Polyclonal/oligoclonal Clonal TRGV10*01 or TRGV10*02 TRGV10*01 or TRGV10*02
24 62 M Caucasian Forearm Plaque 27.0% Polyclonal/oligoclonal Clonal TRGV9*01 TRGV2*02
25 62 M Caucasian Arm Patch 21.0% Polyclonal/oligoclonal Clonal TRGV9*02 TRGV3*01
26 74 M Caucasian Lower
extremity
Patch 6.9% Polyclonal/oligoclonal Clonal TRGV10*01 or TRGV10*02 TRGV10*01 or TRGV10*02
27* 74 F African American Arm Patch 1.0% Polyclonal/oligoclonal Polyclonal/oligoclonal TRGV4*02 TRGV9*01
28 57 F African American Face Plaque 9.6% Polyclonal/oligoclonal Clonal TRGV3*01 TRGV3*01 or TRGV5*01
29 57 F African American Abdomen Plaque 5.6% Polyclonal/oligoclonal Clonal TRGV3*01 TRGV3*01 or TRGV5*01
30 52 F African American Forearm Tumor 64.1% Polyclonal/oligoclonal Clonal TRGV10*01 or TRGV10*02 TRGV2*02
31 52 F African American Hand Tumor 80.3% Polyclonal/oligoclonal Clonal TRGV10*01 or TRGV10*02 TRGV10*01 or TRGV10*02
32 63 F Caucasian Abdomen Plaque 29.8% Polyclonal/oligoclonal Clonal TRGV4*02 TRGV8*01
33 63 F Caucasian Abdomen Plaque 37.4% Polyclonal/oligoclonal Clonal TRGV4*02 TRGV8*01
34* 62 M Caucasian Lower
extremity
Plaque 0.8% Polyclonal/oligoclonal Polyclonal/oligoclonal TRGV10*01 or TRGV10*02 TRGV10*01 or TRGV10*02
T-cell receptor variable identifications are provided for each of the 34 cases included in the analysis.
CE, Capillary electrophoresis; F, female; M, male; NGS, next-generation sequencing.
*Cases were not called clonal by NGS.
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